Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial

Overview of attention for article published in The Lancet, May 2020

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (96th percentile)

Mentioned by

news: 153 news outlets
blogs: 13 blogs
policy: 3 policy sources
twitter: 1299 X users
patent: 3 patents

facebook: 9 Facebook pages
wikipedia: 2 Wikipedia pages
f1000: 1 research highlight platform
video: 2 YouTube creators

Citations

dimensions_citation: 1247 Dimensions

Readers on

mendeley: 1606 Mendeley

Summary News Blogs Policy documents X Patents Facebook Wikipedia Research highlights YouTube Dimensions citations

So far, Altmetric has seen 3 patents that reference this research output.

METHOD FOR ENHANCING INNATE IMMUNE RESPONSE

Application WO-2022255411-A1

World Intellectual Property Organisation (WIPO)

INHALED INTERFERON-BETA FOR IMPROVING OUTCOME IN SARS-COV-2 INFECTED PATIENTS

Application WO-2022018422-A1

World Intellectual Property Organisation (WIPO)

HYDROLYSABLE TANNINS FOR USE IN MITIGATING ACUTE RESPIRATORY DISTRESS SYNDROME

Application WO-2021207399-A1

World Intellectual Property Organisation (WIPO)